Grupo Zendal | Prensa

El Grupo Zendal

Zendal Portugal

Biofarmacéuticos

Ediciones anteriores

NOTICIA

01 · 06 · 2026

International partnership strengthens efforts to accelerate the development of the MTBVAC tuberculosis vaccine candidate

Contacto de prensa

01 · 06 · 2026International partnership strengthens efforts to accelerate the development of the MTBVAC tuberculosis vaccine candidate

22 · 05 · 2026Biofabri advances a potential new solution for bladder cancer

24 · 04 · 2026Immunization, key to strengthening public health against future health threats

10 · 04 · 2026Zendal obtains European approval for the first trivalent bluetongue vaccine for sheep (serotypes 1, 4 and 8)

24 · 02 · 2026ZENDAL holds an internal scientific session in O Porriño with the participation of Luis Blanco from CSIC

19 · 02 · 2026Biofabri Appoints Rolando Pajón to Strengthen the Late-Stage Development of Its Tuberculosis Vaccine Candidate

14 · 11 · 2025The Zendal Group presents its Human and Animal Health Awards in a ceremony marking its sixth edition

06 · 11 · 2025Research on aggressive triple-negative breast cancer earns CINBIO (University of Vigo) the Zendal Award in Human Health.

30 · 07 · 2025Leading scientific experts join the jury of the VI International Zendal Awards

05 · 06 · 2025The Sixth Edition of the International Zendal Awards is Now Open for Applications

18 · 03 · 2025ZENDAL receives EMA recommendation for its vaccine against EHD

27 · 02 · 2025Biofabri and IAVI announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy trial of the tuberculosis vaccine candidate MTBVAC

1
2
3
4